# Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

> **NCT07003464** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT07003464
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003464, "Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07003464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*